Diabetes pill may shield hearts from chemo damage
NCT ID NCT06888505
Summary
This study tested whether a diabetes drug called dapagliflozin could protect the heart in cancer patients receiving a common but potentially heart-damaging chemotherapy. 90 patients were randomly assigned to take either dapagliflozin or a placebo pill daily for four months alongside their chemotherapy. Researchers measured heart function before and after treatment to see if the drug helped prevent chemotherapy-related heart damage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOTOXICITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azadi Oncology Centre
Duhok, 42001, Iraq
Conditions
Explore the condition pages connected to this study.